NAV-003, A Bispecific Antibody Targeting A Unique Mesothelin Epitope and CD3ε With Improved Cytotoxicity Against Humoral Immunosuppressed Tumors.
Sign Up to like & getrecommendations! Published in 2023 at "European journal of immunology"
DOI: 10.1002/eji.202250309
Abstract: Mesothelin (MSLN) is a cell surface protein over-expressed in a number of cancer types. Several antibody- and cellular-based MSLN targeting agents have been tested in clinical trials where their therapeutic efficacy has been moderate at… read more here.
Keywords: cd3; mesothelin; bispecific antibody; nav 003 ... See more keywords
Influence of antigen density and immunosuppressive factors on tumor-targeted costimulation with antibody-fusion proteins and bispecific antibody-mediated T cell response
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Immunology, Immunotherapy"
DOI: 10.1007/s00262-020-02624-6
Abstract: Target expression heterogeneity and the presence of an immunosuppressive microenvironment can hamper severely the efficiency of immunotherapeutic approaches. We have analyzed the potential to encounter and overcome such conditions by a combinatory two-target approach involving… read more here.
Keywords: antibody; costimulation; immunosuppressive factors; expression ... See more keywords
TIM-3 blockade combined with bispecific antibody MT110 enhances the anti-tumor effect of γδ T cells
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Immunology, Immunotherapy"
DOI: 10.1007/s00262-020-02638-0
Abstract: As ideal cells that can be used for adoptive cell therapy, γδ T cells are a group of homogeneous cells with high proliferative and tumor killing ability. However, γδ T cells are apt to apoptosis… read more here.
Keywords: antibody mt110; anti tumor; tim; bispecific antibody ... See more keywords
Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Immunology, Immunotherapy"
DOI: 10.1007/s00262-020-02679-5
Abstract: CD47, an immune checkpoint receptor frequently unregulated in various blood and solid tumors, interacts with ligand SIPRα on innate immune cells, and conveys a “do not eat me” signal to inhibit macrophage-mediated tumor phagocytosis. This… read more here.
Keywords: cd47; bispecific antibody; cd47 bispecific; activity ... See more keywords
Bispecific antibody CD73xEpCAM selectively inhibits the adenosine-mediated immunosuppressive activity of carcinoma-derived extracellular vesicles.
Sign Up to like & getrecommendations! Published in 2021 at "Cancer letters"
DOI: 10.1016/j.canlet.2021.08.037
Abstract: Tumor-derived extracellular vesicles (EVs) carry potent immunosuppressive factors that affect the antitumor activities of immune cells. A significant part of the immunoinhibitory activity of EVs is attributable to CD73, a GPI-anchored ecto-5'-nucleotidase involved in the… read more here.
Keywords: extracellular vesicles; derived extracellular; cd73xepcam; bispecific antibody ... See more keywords
Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment.
Sign Up to like & getrecommendations! Published in 2017 at "Cancer cell"
DOI: 10.1016/j.ccell.2017.02.002
Abstract: We identified B cell maturation antigen (BCMA) as a potential therapeutic target in 778 newly diagnosed and relapsed myeloma patients. We constructed an IgG-based BCMA-T cell bispecific antibody (EM801) and showed that it increased CD3+… read more here.
Keywords: myeloma; cell bispecific; bcma cell; antibody em801 ... See more keywords
Fed-batch production assessment of a tetravalent bispecific antibody: a case study on piggyBac stably transfected HEK293 cells.
Sign Up to like & getrecommendations! Published in 2021 at "New biotechnology"
DOI: 10.1016/j.nbt.2021.07.002
Abstract: The transition from preclinical biological drug development into clinical trials requires an efficient upscaling process. In this context, bispecific antibody drugs are particularly challenging due to their propensity to form aggregates and generally produce low… read more here.
Keywords: bispecific antibody; antibody; fed batch; tetravalent bispecific ... See more keywords
Removing half antibody byproduct by protein A chromatography during the purification of a bispecific antibody.
Sign Up to like & getrecommendations! Published in 2020 at "Protein expression and purification"
DOI: 10.1016/j.pep.2020.105635
Abstract: Half antibody (one half of an antibody which comprises a heavy chain and a light chain) is a common byproduct in bispecific antibody (bsAb) production and in many cases it represents the major product-related impurity.… read more here.
Keywords: protein; antibody; bispecific antibody; byproduct ... See more keywords
CD3 Target Affinity Chromatography Mass Spectrometry as a New Tool for Function-Structure Characterization of T-Cell Engaging Bispecific Antibody Proteoforms and Product-Related Variants.
Sign Up to like & getrecommendations! Published in 2023 at "Analytical chemistry"
DOI: 10.1021/acs.analchem.2c03827
Abstract: T-cell engaging bispecific antibodies (TCBs) targeting CD3 and tumor-specific antigens are very promising therapeutic modalities. Since CD3 binding is crucial for the potency of TCBs, understanding the functional impact of CD3 antigen-binding fragment modifications is… read more here.
Keywords: cd3; cell; bispecific antibody; cell engaging ... See more keywords
Synthesis of Bispecific Antibody Conjugates Using Functionalized Poly-ADP-ribose Polymers.
Sign Up to like & getrecommendations! Published in 2023 at "Biochemistry"
DOI: 10.1021/acs.biochem.2c00718
Abstract: Poly-ADP-ribose (PAR) is a natural type of polymer derived from enzymatic reactions catalyzed by cellular poly(ADP-ribose) polymerases (PARPs). Given its notable solubility and biocompatibility, the PAR polymer may function as effective carriers for therapeutics in… read more here.
Keywords: poly adp; adp ribose; par polymer; bispecific antibody ... See more keywords
Bispecific Antibody Binding To RANKL and Osteonectin with Enhanced Localization to the Bone.
Sign Up to like & getrecommendations! Published in 2017 at "Molecular pharmaceutics"
DOI: 10.1021/acs.molpharmaceut.7b00501
Abstract: Therapeutics reducing bone turnover, such as denosumab (Dmab), an anti-RANKL antibody, can provide treatments for patients with bone destruction. However, some patients with osteoporosis or localized primary bone tumors and many patients with various types… read more here.
Keywords: rankl osteonectin; bone; antibody; bispecific antibody ... See more keywords